Aquestive Therapeutics, Inc.AQSTEarnings & Financial Report
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
AQST Q4 FY2025 Key Financial Metrics
Revenue
$13.0M
Gross Profit
$7.2M
Operating Profit
$-28.8M
Net Profit
$-31.9M
Gross Margin
55.2%
Operating Margin
-221.6%
Net Margin
-244.8%
YoY Growth
9.7%
EPS
$-0.26
Aquestive Therapeutics, Inc. Q4 FY2025 Financial Summary
Aquestive Therapeutics, Inc. reported revenue of $13.0M (up 9.7% YoY) for Q4 FY2025, with a net profit of $-31.9M (down 86.8% YoY) (-244.8% margin). Cost of goods sold was $5.8M, operating expenses totaled $36.0M.
Key Financial Metrics
| Total Revenue | $13.0M |
|---|---|
| Net Profit | $-31.9M |
| Gross Margin | 55.2% |
| Operating Margin | -221.6% |
| Report Period | Q4 FY2025 |
Aquestive Therapeutics, Inc. Annual Revenue by Year
Aquestive Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.5M).
Aquestive Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aquestive Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.0M | +9.7% | $-31.9M | -244.8% |
| Q3 FY2025 | $12.8M | -5.4% | $-15.4M | -120.6% |
| Q2 FY2025 | $10.0M | -50.2% | $-13.5M | -135.4% |
| Q1 FY2025 | $8.7M | -27.7% | $-22.9M | -263.0% |
| Q4 FY2024 | $11.9M | -10.1% | $-17.1M | -143.7% |
| Q3 FY2024 | $13.5M | +4.2% | $-11.5M | -85.0% |
| Q2 FY2024 | $20.1M | +51.8% | $-2.7M | -13.7% |
| Q1 FY2024 | $12.1M | +8.3% | $-12.8M | -106.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $20.1M | $13.5M | $11.9M | $8.7M | $10.0M | $12.8M | $13.0M |
| YoY Growth | 8.3% | 51.8% | 4.2% | -10.1% | -27.7% | -50.2% | -5.4% | 9.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $129.5M | $117.6M | $110.0M | $101.4M | $102.2M | $93.7M | $163.6M | $160.4M |
| Liabilities | $165.8M | $153.1M | $155.4M | $161.6M | $163.2M | $166.3M | $167.7M | $194.1M |
| Equity | $-36.3M | $-35.5M | $-45.4M | $-60.2M | $-60.9M | $-72.6M | $-4.1M | $-33.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.4M | $-7.0M | $-11.9M | $-6.5M | $-23.4M | $-7.9M | $-12.6M | $-8.5M |